Godavari Biorefineries has announced the successful validation of its European patent for a novel anti-cancer molecule in Spain, the United Kingdom, and as a unitary patent across multiple European Union member states.

• Therapeutic Potential: The patented molecule has demonstrated preclinical efficacy against cancer cells and cancer stem cells and is being developed as a potential treatment for cancers including breast and prostate cancer.
• Clinical Development: The molecule is currently undergoing a Phase 1a clinical trial to evaluate its safety in healthy volunteers and patients with advanced solid tumours.
• Development Programme: Clinical development is being led by Sathgen Therapeutics, the company’s clinical-stage biotechnology division focused on advancing novel cancer and antiviral therapies.

This summary is based on a publication on the Godavari Biorefineries Ltd website.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.